Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Restoration Robotics, Inc., (San Jose, CA) is a medical device company developing ...
Restoration Robotics, Inc., (San Jose, CA) is a...
Evelo develops and sells electric bicycles using a direct-to-consumer distribution...
Evelo develops and sells electric bicycles usin...
iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are...
iRhythm is a digital healthcare company redefin...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therap...
AGTC is a clinical-stage biotechnology company ...
Cool your patients to a target temperature of 33ÂşC in about 30 minutes with Life ...
Cool your patients to a target temperature of 3...
Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company. We ...
Corvus Pharmaceuticals is a clinical science-dr...
Join the National Investor Network and get the latest information with your interests in mind.